Clinical trials: Astrocytoma
Glioma, Glioblastoma
Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)
Background Currently, no standard treatment exists for patients with recurrent glioblastoma multiforme (rGBM) and used 2nd line treatments have low (up to max. 20%) response rates and very modest response duration (months).
- Trial name
- HUTMZ (NCT03463733)
- Testing
- Hydroxyurea, Temozolomide
- Where
- Netherlands
- Volunteers
- 54 people
- Sponsor
- M.E. van Linde
Brain and Central Nervous System Tumors, Metastatic Cancer
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00002752
- Testing
- iodine I 131 monoclonal antibody 81C6
- Where
- United States
- Sponsor
- Duke University
Brain and Central Nervous System Tumors, Lymphoma
Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Retinoblastoma
- Trial name
- NCT00053118
- Testing
- filgrastim, carboplatin, etoposide
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Roswell Park Cancer Institute
Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3
Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma
This phase 1b trial studies the side effects and best dose of telaglenastat in combination with radiation therapy and temozolomide in treating patients with IDH-mutated diffuse or anaplastic astrocytoma.
- Trial name
- NCT03528642
- Testing
- Questionnaire Administration, Radiation Therapy, Telaglenastat Hydrochloride
- Where
- 25 sites in United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma of Cerebellum
DLL3 CAR-T Therapy Targeting Brain Tumors
The purpose of this study is to assess the feasibility, safety and efficacy of Delta-like ligand 3 (DLL3)-specific CAR-T cell therapy in patients with DLL3 positive brain tumors including glioblastomas and diffused intrinsic…
- Trial name
- NCT07180927
- Testing
- 4SCAR DLL3 T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Anaplastic Glioma of Brain, Glioblastoma Multiforme
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
The goal of this clinical research study is to learn if the combination of 6-Thioguanine, Xeloda (capecitabine), and Celebrex (celecoxib) with Temodar (temozolomide) or Lomustine (CCNU) is effective in the treatment of recurrent…
- Conditions
- Anaplastic Glioma of Brain, Glioblastoma Multiforme, Brain Cancer
- Trial name
- NCT00504660
- Testing
- Capecitabine, Celecoxib (Celebrex), Temozolomide
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- M.D. Anderson Cancer Center
Brain and Central Nervous System Tumors, Chordoma
Polyvinylpyrrolidone-Sodium Hyaluronate Gel in Reducing Pain From Oral Mucositis in Young Patients With Cancer
RATIONALE: Polyvinylpyrrolidone-sodium hyaluronate gel may lessen the pain of oral mucositis, or mouth sores, in patients undergoing treatment for cancer.
- Conditions
- Brain and Central Nervous System Tumors, Chordoma, Kidney Cancer, Leukemia
- Trial name
- NCT00349024
- Testing
- polyvinylpyrrolidone-sodium hyaluronate gel
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 50 people
- Sponsor
- Children's Cancer and Leukaemia Group
Brain Tumors, Central Nervous System Tumors
Combination Chemotherapy in Treating Children With Progressive Brain Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002944
- Testing
- carboplatin, lomustine, procarbazine hydrochloride
- Where
- 204 sites in United States, Australia and 4 more
- Volunteers
- 428 people
- Sponsor
- Children's Oncology Group
Glioma, BRAF V600E
A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas
This is a surgical biospecimen collection study. The purpose of this study is to understand how much of two drugs (dabrafenib and trametinib) are able to penetrate brain tumors and turn off the RAF signaling pathway.
- Conditions
- Glioma, BRAF V600E, Pleomorphic Xantho-Astrocytoma, Glioblastoma
- Trial name
- NCT03593993
- Testing
- Surgical Cohort
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as temozolomide, vincristine, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00138216
- Testing
- irinotecan hydrochloride, temozolomide, vincristine sulfate
- Where
- 18 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- Children's Oncology Group
Brain and Central Nervous System Tumors
Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of phenylacetate in treating children with recurrent or…
- Trial name
- NCT00003241
- Testing
- phenylacetate
- Where
- 6 sites in United States
- Sponsor
- Texas Children's Cancer Center
Neoplasms
Continued Treatment for Participants Enrolled in Studies of BXQ-350
This is a study to allow continued treatment for participants enrolled in studies of BXQ-350. This study is intended only for those who have completed the required study observation period or are still on treatment upon the…
- Trial name
- ETERNITI (NCT04404569)
- Testing
- BXQ-350
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Bexion Pharmaceuticals, Inc.
Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS)
Phase I Study of APX005M in Pediatric Central Nervous System Tumors
This phase I trial studies the side effects and best dose of APX005M in treating younger patients with primary malignant central nervous system tumor that is growing, spreading, or getting worse (progressive), or newly diagnosed…
- Conditions
- Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS), CNS Primary Tumor, Not Otherwise Specified (NOS), Ependymoma, Not Otherwise Specified (NOS)
- Trial name
- NCT03389802
- Testing
- APX005M treatment for recurrent or refractory primary malignant CNS tumor patients, APX005M treatment for newly diagnosed DIPG patients
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- Pediatric Brain Tumor Consortium
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
This phase I trial is studying the side effects and best dose of vorinostat when given together with temozolomide in treating young patients with relapsed or refractory primary brain tumors or spinal cord tumors.
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germinoma
- Trial name
- NCT01076530
- Testing
- vorinostat, temozolomide, diagnostic laboratory biomarker analysis
- Where
- 9 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
The objective of this study is to evaluate the safety, tolerability, efficacy profile, and effect on growth and development of vorasidenib in pediatric participants aged 12 to < 18 years old with grade 2 glioma with an IDH1 or…
- Trial name
- NCT07286292
- Testing
- Vorasidenib
- Where
- 5 sites in United States, Australia
- Volunteers
- 10 people
- Sponsor
- Institut de Recherches Internationales Servier (I.R.I.S.)
Glioma, Glioma of Brain
Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma
This is a 2 strata pilot trial within the Pacific Pediatric Neuro-Oncology Consortium (PNOC). The study will use a new treatment approach based on each patient's tumor gene expression, whole-exome sequencing (WES), targeted panel…
- Conditions
- Glioma, Glioma of Brain, Cancer, Pediatric Cancer
- Trial name
- PNOC008 (NCT03739372)
- Testing
- Specialized tumor board recommendation
- Where
- 12 sites in United States
- Volunteers
- 44 people
- Sponsor
- University of California, San Francisco
Neurofibromatosis 1 (NF1)
Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma
This is a phase 2, open label, parallel multi-arm study of mirdametinib in combination with radiation in participants with recurrent sporadic glioblastoma (GBM) harboring NF1 alterations (Cohort 1); participants with NF1 with a…
- Trial name
- NF118 (NCT07521657)
- Testing
- mirdametinib with radiation, mirdametinib
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Alabama at Birmingham
Childhood High-grade Cerebral Astrocytoma, Childhood Oligodendroglioma
Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma
This phase II trial is studying how well tipifarnib works in treating young patients with recurrent or progressive high-grade glioma, medulloblastoma, primitive neuroectodermal tumor, or brain stem glioma.
- Conditions
- Childhood High-grade Cerebral Astrocytoma, Childhood Oligodendroglioma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma
- Trial name
- NCT00070525
- Testing
- tipifarnib
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, All Types, Cancer of Liver
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any…
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck
- Trial name
- PIONEER (NCT03896958)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- SpeciCare
Ewing's Sarcoma, Osteosarcoma
Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors
The best treatment for recurrent cancers or those that do not respond to therapies is not known. Typically, patients with these cancers receive a combination of cancer drugs (chemotherapy), surgery, or radiation therapy.
- Conditions
- Ewing's Sarcoma, Osteosarcoma, Astrocytoma, Atypical Teratoid/Rhabdoid Tumor
- Trial name
- Aflac ST0901 (NCT01331135)
- Testing
- sirolimus
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Emory University